✦ LIBER ✦

M.P.5.09 Pharmacological chaperone therapy for the treatment of Pompe disease: Deoxynojirimycin increases lysosomal levels and specific activity of acid alpha-glucosidase

✍ Scribed by B. Wustman; A. Powe Jr.; J. Flanagan; R. Khanna; W. Liang; X. Wu; R. Dhulipala; R. Soska; E. Smith; C. Pine; E. Benjamin; D. Lockhart; K. Valenzano; H. Do

Book ID: 116793274
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 62 KB
Volume: 17
Category: Article
ISSN: 0960-8966
DOI: 10.1016/j.nmd.2007.06.426

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The pharmacological chaperone 1-deoxynoj

The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase

✍ John J. Flanagan; Barbara Rossi; Katherine Tang; Xiaoyang Wu; Kirsten Mascioli; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 490 KB

Pompe disease is a lysosomal storage disorder (LSD) caused by mutations in the gene that encodes acid a-glucosidase (GAA). Recently, small molecule pharmacological chaperones have been shown to increase protein stability and cellular levels for mutant lysosomal enzymes and have emerged as a new ther

G.P.8.05 The pharmacological chaperone A

G.P.8.05 The pharmacological chaperone AT2220 increases mutant acid alpha-glucosidase levels and reduces tissue glycogen in a mouse model of Pompe disease

✍ R. Khanna; R. Soksa; J. Feng; Y. Lun; A.C. Powe; J. Flanagan; H. Do; D.J. Lockha 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 39 KB

G.P.11.05 The pharmacological chaperone

G.P.11.05 The pharmacological chaperone AT2220 increases trafficking, processing, and cellular activity of acid α-glucosidase and is a potential new treatment for Pompe disease

✍ A.C. Powe; J.F. Flanagan; R. Khanna; X. Wu; W. Liang; R. Dhulipala; T. Yin; K. T 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 49 KB